Asset profile
TE-8105
Peptide
Evidence outlook · lead readout
NCT06471530 · Overweight and Obesity
The reported results come from study designs that frequently fail to replicate under controlled conditions; see the rationale below.
NCT06471530: This was an open-label, non-randomized, dose-escalation study with no placebo or control group, so it cannot show whether any effect is attributable to the drug itself. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
110 competitors in this universe: 34 direct rivals (same mechanism and indication), 16 same-class, 60 same-indication; 101 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| TE-8105: this drug | Phase 1/2 | Peptide | GLP-1 receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| ASC30 | Phase 3 | Small molecule | GLP-1 receptor | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| CX11 | Phase 3 | Small molecule | GLP-1 receptor | ||
| DA-302168S | Phase 3 | Small molecule | GLP-1 receptor | ||
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | ||
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | ||
| GZR18 | Phase 3 | Peptide | GLP-1 receptor | ||
| HDM1002 | Phase 3 | Small molecule | GLP-1 receptor | ||
| HRS-7535 | Phase 3 | Small molecule | GLP-1 receptor |
…and 95 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
28 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.